Acromegaly
Mostrando 13-24 de 105 artigos, teses e dissertações.
-
13. The position of combined medical treatment in acromegaly
ABSTRACT Advances in combination medical treatment have offer new perspectives for acromegaly patients with persistent disease activity despite receiving the available medical monotherapies. The outcomes of combination medical treatment may reflect both additive and synergistic effects. This review focuses on combination medical treatment and its current pos
Arch. Endocrinol. Metab.. Publicado em: 10/01/2020
-
14. Insulin signaling in the whole spectrum of GH deficiency
ABSTRACT GH is one of the insulin counterregulatory hormones which acts in the opposite way to insulin, increasing the glucose production by the liver and kidneys and decreasing glucose uptake from peripheral tissues, thus being a hyperglycemic hormone. When in excess, as in acromegaly, it induces glucose intolerance and diabetes. As expected, patients with
Arch. Endocrinol. Metab.. Publicado em: 10/01/2020
-
15. Personalized approach to growth hormone replacement in adults
ABSTRACT Growth hormone (GH) deficiency (GHD) in adults is well-characterized and includes abnormal body composition, reduced bone mass, an adverse cardiovascular risk profile, and impaired quality of life. In the early 1990s, it was also shown that patients with hypopituitarism without GH replacement therapy (GHRT) had excess mortality. Today, GHRT has been
Arch. Endocrinol. Metab.. Publicado em: 10/01/2020
-
16. Pegvisomant in acromegaly: a multicenter real-life study in Argentina
ABSTRACT Objective To describe the long term safety and efficacy of pegvisomant (PEGV), and the predictors of treatment response in patients with acromegaly in the real life setting. Subjects and methods We retrospectively reviewed the clinical, hormonal and radiological data of acromegalic patients treated with PEGV in 17 Argentine centers. Results Se
Arch. Endocrinol. Metab.. Publicado em: 22/08/2019
-
17. Pegvisomant for acromegaly: does it always works?
Arch. Endocrinol. Metab.. Publicado em: 22/08/2019
-
18. Brazilian multicenter study on pegvisomant treatment in acromegaly
ABSTRACT Objective Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a real-life, Brazilian multicenter study. Subjects and methods Characteristics of acromegaly patients treated with PEGV were reviewed at diagnosis, just before and during treatment. All patients with at least two IGF-I measurements on PEGV were include
Arch. Endocrinol. Metab.. Publicado em: 29/07/2019
-
19. Clinical and functional variables can predict general fatigue in patients with acromegaly: an explanatory model approach
ABSTRACT Objective To evaluate whether hormonal profile, arterial function, and physical capacity are predictors of fatigue in patients with acromegaly. Subjects and methods: This is a cross-sectional study including 23 patients. The subjects underwent a Modified Fatigue Impact Scale (MFIS) assessment; serum growth hormones (GH) and IGF-1 measurements; pul
Arch. Endocrinol. Metab.. Publicado em: 25/04/2019
-
20. Correlation analysis between short-term insulin-like growth factor-I and glucose intolerance status after transsphenoidal adenomectomy in acromegalic patients: a large retrospective study from a single center in China
ABSTRACT Objectives: Our study aimed to investigate the associations of glucose tolerance status with insulin-like growth factor-I (IGF-I) and other clinical laboratory parameters of acromegalic patients before and after the patients underwent transsphenoidal adenomectomy (TSA) by conducting a single-center, retrospective study. Subjects and methods: A tot
Arch. Endocrinol. Metab.. Publicado em: 21/03/2019
-
21. Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly
Pituitary adenomas account for 10–15% of primary intracranial tumors. Growth hormone (GH)-secreting adenomas account for 13% of all pituitary adenomas and cause acromegaly. These tumors can be aggressive, invade surrounding structures and are highly recurrent. The objective of this study was to evaluate E-cadherin, Slug and neural cell adhesion molecule (N
Braz J Med Biol Res. Publicado em: 11/12/2017
-
22. Long-term follow-up of patients with elevated IGF-1 and nadir GH > 0.4 µg/L but < 1 µg/L
ABSTRACT Objective To report the results of initial investigation and after 5 years of patients with a suspicious clinical scenario for acromegaly, elevated IGF-1, and nadir GH during an oral glucose tolerance test (OGTT) > 0.4 µg/L but < 1 µg/L. Subjects and methods Seventeen patients who had elevated IGF-1 (outside puberty and pregnancy) in two measu
Arch. Endocrinol. Metab.. Publicado em: 18/09/2017
-
23. Biochemical diagnosis of acromegaly without a typical clinical phenotype: what are the concerns?
Arch. Endocrinol. Metab.. Publicado em: 2017-09
-
24. Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report
OBJECTIVE: To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro. METHODS: Cross-sectional and retrospective study of thirty cases treated over a period of two decades. RESULTS: 17 men (56.7%) aged 14-67 years and 13 women aged 14-86 years were analyzed. Twenty-one patients underwent transphen
Clinics. Publicado em: 2017-04